Glenmark Pharmaceuticals Limited (NSE: GLENMARK)

Glenmark Pharmaceuticals Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2024	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Cash & Equivalents	-	16,583	11,592	14,105	11,381	11,103
Short-Term Investments	-	57.81	90.67	57.33	93.4	81.87
Cash & Short-Term Investments	16,595	16,641	11,683	14,163	11,474	11,185
Cash Growth	12.91%	42.44%	-17.51%	23.43%	2.59%	11.27%
Accounts Receivable	-	18,584	36,652	31,011	25,721	24,090
Other Receivables	-	8,225	5,743	5,576	4,797	4,576
Receivables	-	26,809	42,394	36,588	30,517	28,666
Inventory	-	25,131	23,736	24,998	22,768	21,356
Prepaid Expenses	-	266.9	2,275	2,199	2,198	1,457
Other Current Assets	-	5,434	27,167	4,876	6,638	5,373
Total Current Assets	-	74,281	107,255	82,823	73,596	68,036
Property, Plant & Equipment	-	35,375	41,951	46,117	41,756	40,683
Long-Term Investments	-	7,958	472.77	556.64	518.95	507.33
Goodwill	-	673.59	736.19	600.19	580.11	528.99
Other Intangible Assets	-	12,672	23,427	22,254	22,769	21,292
Long-Term Deferred Tax Assets	-	10,497	18,059	16,861	15,347	14,557
Other Long-Term Assets	-	2,130	1,816	1,620	1,469	1,243
Total Assets	-	143,586	193,717	170,833	156,036	146,848
Accounts Payable	-	25,359	20,004	22,887	22,378	21,258
Accrued Expenses	-	12,473	14,427	7,168	6,346	6,085
Short-Term Debt	-	8,334	3,500	3,700	5,130	4,426
Current Portion of Long-Term Debt	-	1,572	1,456	7,286	2,856	3,830
Current Portion of Leases	-	886.43	830.39	916.78	742.54	859.97
Current Income Taxes Payable	-	2,910	984.98	931.2	501.2	407.13
Other Current Liabilities	-	6,652	9,848	4,005	4,057	4,393
Total Current Liabilities	-	58,186	51,051	46,894	42,010	41,260
Long-Term Debt	-	-	38,521	25,717	38,888	40,430
Long-Term Leases	-	1,517	1,771	2,000	2,240	2,313
Long-Term Deferred Tax Liabilities	-	2.8	5.14	314.95	287.49	164.48
Other Long-Term Liabilities	-	5,405	3,976	1,525	1,967	1,979
Total Liabilities	-	65,111	95,324	76,452	85,393	86,147
Common Stock	-	282.19	282.17	282.17	282.17	282.17
Additional Paid-In Capital	-	16,866	16,854	16,854	16,854	16,854
Retained Earnings	-	80,160	96,026	93,564	73,791	64,752
Comprensive Income & Other	-	-18,828	-18,422	-19,834	-20,281	-21,183
Total Common Equity	78,479	78,479	94,739	90,866	70,646	60,705
Minority Interest	-	-3.8	3,653	3,515	-3.54	-3.92
Shareholders' Equity	78,475	78,475	98,393	94,381	70,643	60,701
Total Liabilities & Equity	-	143,586	193,717	170,833	156,036	146,848
Total Debt	12,309	12,309	46,079	39,620	49,857	51,860
Net Cash (Debt)	4,285	4,331	-34,396	-25,458	-38,383	-40,675
Net Cash Per Share	15.19	15.35	-121.90	-90.22	-136.03	-144.15
Filing Date Shares Outstanding	282.15	282.19	282.17	282.17	282.17	282.17
Total Common Shares Outstanding	282.15	282.19	282.17	282.17	282.17	282.17
Working Capital	-	16,095	56,205	35,929	31,586	26,776
Book Value Per Share	278.09	278.11	335.75	322.03	250.37	215.14
Tangible Book Value	65,134	65,134	70,576	68,012	47,297	38,884
Tangible Book Value Per Share	230.80	230.82	250.12	241.04	167.62	137.80
Land	-	461.25	423.45	688.97	581.31	575.28
Buildings	-	17,556	16,069	17,211	13,053	12,501
Machinery	-	32,155	32,052	34,167	28,352	26,738
Construction In Progress	-	4,193	10,658	9,211	12,178	10,906

Source: S&P Capital IQ. Standard template. Financial Sources.